Clin2
NCT06718686Possibly a fitRecruiting

Rifaximin for Dementia

Dementia Alzheimer TypeDementia Associated With Cerebrovascular Disease

Part of Brain & nervous system, Heart & circulation, Mental health clinical trials.

This study tests a new antibiotic (rifaximin) to see if it can help people with mild to moderate Alzheimer's or vascular dementia. You and a caregiver would come to the clinic for check-ups to monitor how you're doing.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
20 people
Ages
65 years and older
Study type
Interventional

Who can take part

  • You have Alzheimer's disease or vascular dementia that is mild or moderate.
  • You are 65 years old or older and live at home or in the community.
  • You have a caregiver (like a family member) who can come to all study visits and help with the study.
  • You and your caregiver are both fluent in English.
  • You have not taken any antibiotics in the last 6 months.
  • You do not have severe agitation, hallucinations, depression, or other unstable medical problems.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07203846Not yet recruiting· Phase 4
Rifaximin for better blood thinning after heart attack

This trial tests if adding the gut antibiotic rifaximin to ticagrelor (a blood thinner) can further reduce the risk of blood clots in people who've had a heart attack. It's for patients whose platelets are still too active despite taking ticagrelor.

Bydgoszcz, Cuiavian-Pomeranian
NCT05587036Recruiting· Phase 2/Phase 3
Rifaximin study to see how gut bacteria affect mood

This trial tests whether a gut-targeting antibiotic called rifaximin changes the gut microbiome (gut bacteria) and affects emotion. It is looking for healthy men so any mood or gut changes can be more clearly linked to the study treatment.

Leuven
NCT07185932Recruiting· Early Phase 1
Rifaximin for fatty liver with metabolic issues

This trial tests if rifaximin, a gut-targeted antibiotic, can help people with fatty liver disease who also have metabolic problems like obesity or diabetes. You need a recent fatty liver diagnosis and a liver fat level of at least 8% on an MRI scan.

Shanghai, Shanghai Municipality
NCT07285785Recruiting· Phase 4
Rifaximin for children with acute diarrhea

This study tests whether a medicine called rifaximin, taken along with oral rehydration solution, helps children aged 6 to 11 recover faster from acute (short-lasting) diarrhea that is likely caused by a bacterial infection. The study compares rifaximin plus oral rehydration versus oral rehydration alone.

Lynwood, California
NCT06652087Recruiting
Testing rifaximin for heart failure with preserved pumping

This trial tests whether the antibiotic rifaximin (taken by mouth) can improve heart function in people with a type of heart failure where the heart pumps well but is still weak (HFpEF). Rifaximin might help by changing the bacteria in your gut.

Moscow
NCT07591727Not yet recruiting· Phase 1/Phase 2
Gut-X-001 Oral Medication for Alzheimer's Disease

This study tests an experimental oral medication called Gut-X-001 that may help slow thinking and memory problems in people with Alzheimer's disease by working through the gut. You'll take the medication for several months while doctors monitor your cognitive health and safety.

Hear when a new Dementia Alzheimer Type trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.